The fact that we found some evidence for a clinical role of CD8+ cells only for some cancer types, but not for ovarian, breast and pancreatic cancer, may reflect that TIL quantification is clinically less relevant in these tumors. The gene discussed is CD8A; the disease is pancreatic neoplasm.